Long-term safety and effectiveness of eculizumab in patients with AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance

被引：0
|
作者：
Nakahara, Jin [1 ]
Nakashima, Ichiro [2 ]
Yokote, Hiroaki [3 ]
Manabe, Yasuhiro [4 ]
Okamura, Kazumi [5 ]
Hasegawa, Kou [5 ]
Fujihara, Kazuo [6 ,7 ]
机构：
[1] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan
[2] Tohoku Med & Pharmaceut Univ, Div Neurol, Sendai, Japan
[3] Tokyo Metropolitan Komagome Hosp, Dept Neurol, Tokyo, Japan
[4] Natl Hosp Org Okayama Med Ctr, Dept Neurol, Okayama, Japan
[5] Alexion Pharma GK, Tokyo, Japan
[6] Fukushima Med Univ, Fukushima, Japan
[7] Southern TOHOKU Res Inst Neurosci STRINS, Koriyama, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P010/1870
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [11] Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan
    Nakashima, Ichiro
    Nakahara, Jin
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [12] Long-term safety, effectiveness, and corticosteroid sparing effects of eculizumab in patients with AQP4Ab+neuromyelitis optica spectrum disorder: realworld data from Japan
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Isobe, Noriko
    Yajima, Toshitaka
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 143 - 144
  • [13] Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance
    Yamamura, Takashi
    Isobe, Noriko
    Kawachi, Izumi
    Nohara, Chiyoko
    Miyazaki, Yusei
    Tomita, Minami
    Tsumuraya, Takahiko
    Yamashita, Katsuhisa
    Nakahara, Jin
    Nakashima, Ichiro
    Fujihara, Kazuo
    NEUROLOGY AND THERAPY, 2024, 13 (05) : 1361 - 1383
  • [14] Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Pittock, Sean J.
    Berthele, Achim
    Fujihara, Kazuo
    Kim, Ho Jin
    Levy, Michael
    Palace, Jacqueline
    Nakashima, Ichiro
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Allen, Kerstin
    Fujita, Kenji P.
    Yountz, Marcus
    Armstrong, Roisin
    NEUROLOGY, 2020, 94 (15)
  • [15] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Rie Kanamori
    Shiho Yamane
    Takeshi Seto
    Advances in Therapy, 2021, 38 : 4949 - 4960
  • [16] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Kanamori, Rie
    Yamane, Shiho
    Seto, Takeshi
    ADVANCES IN THERAPY, 2021, 38 (09) : 4949 - 4960
  • [17] Safety and Effectiveness of Eculizumab in Japanese Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance Study (P1-1.Virtual)
    Nakashima, Ichiro
    Hoshino, Yo
    Okamura, Kazumi
    Kikui, Hidekazu
    Fujihara, Kazuo
    NEUROLOGY, 2022, 98 (18)
  • [18] Benefits of eculizumab in AQP4+neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
    Palace, Jacqueline
    Wingerchuk, Dean M.
    Fujihara, Kazuo
    Berthele, Achim
    Oreja-Guevara, Celia
    Kim, Ho Jin
    Nakashima, Ichiro
    Levy, Michael
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Pace, Amy
    Yountz, Marcus
    Miller, Larisa
    Armstrong, Roisin
    Pittock, Sean
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 47
  • [19] Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance
    Kuroishi, Naho
    Watananbe, Asuka
    Sakuma, Ryuta
    Ruzicka, Daniel J.
    Hara, Mitsuyoshi
    PLOS ONE, 2019, 14 (01):
  • [20] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
    Sakae Tanaka
    Hideki Mizutani
    Eri Tsuruya
    Ryoko Fukuda
    Kiyoka Kuge
    Naoki Okubo
    Journal of Bone and Mineral Metabolism, 2021, 39 : 463 - 473
12345